Table 5.

Pattern of toxicity and treatment compliance reported by the studies on HIV-positive patients with cervical cancer

			Toxicity (%)
Study	Treatment	Toxicity scale	GIT	GUS	Hem	Skin	Treatment completionon schedule (%)
			Gichangi et al. 43	EBRT NS	G1	NS		NS	NS	NS	NS	NS
Brachy NS	G2	NS		NS	NS	NS	NS
CTH NS	G3	NS		NS	NS	NS	NS
HAART NS	G4	NS		NS	NS	NS	NS
Moodley and Mould 44	EBRT Yes (dose NS)	G1	NS	NS	NS	NS	NS	53%
	Brachy NS	G2	NS	NS	NS	NS	NS
	CTH NS	G3	NS	NS	NS	NS	NS
	HAART NS	G4	NS	NS	NS	NS	NS
Shrivastava et al. 45	EBRT (45–50 Gy)	G1	45	46	NS	NS	RTOG	52%
	Brachy (25–30 Gy –54% of patients)	G2	41	18	NS	NS
	CTH-Nil	G3	9	–	NS	NS
	HAART NS	G4	5	–	NS	NS
Gichangi et al. 15	EBRT (40–50 Gy)	G1	NS	NS	NS	NS	NS
	Brachy Nil	G2	NS	NS	NS	NS
	CTH Nil	G3	} 34	20	–	39		67%
	HAART Nil	G4	NS	NS	NS	NS
Msadabwe 26	EBRT 45 Gy (Mean)	G1	5	8	15	NS	RTOG/WHO	72%
	Brachy 24 Gy in 3#	G2	7	1	7	NS
	CTH Cisp 30 mg/m2 weekly	G3	2	–	4	NS
	HAART Yes	G4	–	–	–	NS
Simonds et al. 29	EBRT 46–50 Gy	G1	NS	NS	NS	NS	NS	45%
	Brachy 20–26 Gy	G2	NS	NS	NS	NS
	CTH Cisp 40 mg/m2	G3	NS	NS	NS	NS
	HAART Yes	G4	NS	NS	NS	NS
Munkukpa 23	EBRT 46–50 Gy	G1	63	58	34	49	NCI-CTC	75%
	Brachy 20-26 Gy	G2	33	35	17	47
	CTH Cisp 80 mg/m2 3 weekly	G3	–	–	5	5.5
	HAART Yes	G4	–	–	5	–
Al-Noseery 27	EBRT 46–50 Gy	G1	84	79.6	84	NS	NCI-CTC	77%
	Brachy 26 Gy	G2
	CTH Cisp 80 mg/m2 3 weekly	G3	6.8	6.1	12.2	NS
	HAART Yes	G4

EBRT, external beam radiotherapy; Brachy, brachytherapy; CTH, chemotherapy; NS, not stated; GUS, genitourinary system; GIT, gastro intestinal system; Hem, hematopoietic system; G, grade, #, fractions of brachytherapy; RTOG, Radiation Therapy Oncology Group; NCI-CTC, National Institute-Common Toxicity Criteria.